Tonix Pharmaceuticals Holding Corp. (TNXP) analyst actions
Rating and price-target actions on TNXP in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the TNXP overview →
3 measured TNXP analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain | Press release | +1.33% | -3.85% | |
| Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital | Press release | -0.66% | -3.58% | |
| Tonix Pharmaceuticals Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum Disorder | Press release | -4.04% | -1.06% |
Keep exploring
More TNXP: earnings → · SEC filings → · TNXP overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| LOXO ONCOLOGY (LOXO) | 526 | 0.00% | 49% |
| Quest Diagnostics Incorporated (DGX) | 524 | +0.03% | 51% |
| STAAR Surgical Company (STAA) | 522 | -0.21% | 44% |
| Surface Oncology, Inc. (SURF) | 521 | -0.69% | 36% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.